RSS-Feed abonnieren
DOI: 10.1055/s-0044-1801287
Clinical Outcomes of Patients with Multiple Myeloma Presenting with Renal Failure
Abstract
Aims and Objective This article studies the clinical outcome of patients with multiple myeloma who have renal failure at presentation.
Methodology Patients with multiple myeloma presenting with serum creatinine of more than or equal to 2 mg/dL from outpatient department at Sri Ram Cancer Centre, Mahatma Gandhi Medical College & Hospital, Jaipur, Rajasthan, India, were screened for baseline serum creatinine and estimated glomerular filtration rate (eGFR). Assessment was done at completion of 6 months from diagnosis—patients' clinical condition, renal response (serum creatinine and eGFR), and disease response as per the International Myeloma Working Group criteria.
Results Final response assessment was done at a follow-up of 6 months. Half of the patients achieved a renal complete response; the highest being in the lenalidomide group (83.3%). Patients with eGFR < 15 mL/min/m2 at presentation fared poorly versus those with eGFR > 15 mL/min/m2. Patients who were dialysis-dependent at baseline had poorer renal responses as compared with those who were dialysis-independent. Out of six patients who were initially dialysis-dependent, four (66.6%) became dialysis-independent after treatment.
Publikationsverlauf
Eingereicht: 22. November 2024
Angenommen: 28. November 2024
Artikel online veröffentlicht:
10. Januar 2025
© 2025. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Bladé J, Fernández-Llama P, Bosch F. et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 1998; 158 (17) 1889-1893
- 2 Rajkumar SV, Dimopoulos MA, Palumbo A. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014; 15 (12) e538-e548
- 3 Yadav P, Cook M, Cockwell P. Current trends of renal impairment in multiple myeloma. Kidney Dis (Basel) 2016; 1 (04) 241-257
- 4 Mohyuddin GR, Hampton J, Aziz M. et al. A systematic review and network meta-analysis of randomized data on efficacy of novel therapy combinations in patients with lenalidomide-refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 2021; 21 (07) 489-496
- 5 Haynes RJ, Read S, Collins GP, Darby SC, Winearls CG. Presentation and survival of patients with severe acute kidney injury and multiple myeloma: a 20-year experience from a single centre. Nephrol Dial Transplant 2010; 25 (02) 419-426
- 6 Dimopoulos MA, Merlini G, Bridoux F. et al; International Myeloma Working Group. Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group. Lancet Oncol 2023; 24 (07) e293-e311
- 7 Zhu W, Chen W. Bortezomib-based treatment for multiple myeloma patients with renal impairment: a systematic review and meta-analysis of observational studies. Medicine (Baltimore) 2016; 95 (46) e5202
- 8 Dimopoulos MA, Sonneveld P, Leung N. et al. International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol 2016; 34 (13) 1544-1557
- 9 Pandey, et al. Beneficial effect of complete response and type of therapy in multiple myeloma. J Clin Oncol 2013; 13 (15) 8541-8541
- 10 Hutchison CA, Bradwell AR, Cook M. et al. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol 2009; 4 (04) 745-754
- 11 Wirk B. Renal failure in multiple myeloma: a medical emergency. Bone Marrow Transplant 2011; 46 (06) 771-783
- 12 Torra R, Bladé J, Cases A. et al. Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol 1995; 91 (04) 854-859
- 13 Nozza A, Siracusano L, Armando S. Bortezomib-dexamethasone combination in a patient with refractory multiple myeloma and impaired renal function. Clin Ther 2006; 28 (06) 953-959
- 14 Roussou M, Kastritis E, Migkou M. et al. Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens. Leuk Lymphoma 2008; 49 (05) 890-895